"Solid results in the year have provided an excellent platform for Ipsen in 2024, an exciting period in which we anticipate four launches and further opportunities to expand the pipeline.

"As Ipsen transforms, improving execution is supporting consistent sales growth, while the productive pipeline is yielding further encouraging results for patients.

“We look forward to more milestones this year and enriching the pipeline over time through additional external-innovation transactions.”

David Loew
CEO

FY 2023 HIGHLIGHTS

- **Core operating income**: €1,001m
- **Core operating margin**: 32.0%
- **Total sales**: €3.13bn (+6.7%)
- **FREE CASH FLOW**: €711m
- **Core earnings per share**: €9.15

**GEOGRAPHIC BREAKDOWN**
- **North America**: 33%
- **Europe**: 40%
- **Rest of World**: 27%

**NEW MEDICINES**
- **Bylvay**
- **Odevixibat**
- **TAZVERIK**
- **sohonos**

**GROWTH PLATFORMS**
- **Dysport (abobotulinumtoxinA)**: +14.5%
- **Decapeptyl**
- **CABOMETYX**
- **Onivyde**
- **+22.9%**
- **+5.9%**
- **+17.3%**

**FY 2024**

- **Anticipated launches**
  - 1L PDAC: U.S.
  - Elafibranor
  - 2L PBC: U.S., E.U.
  - Odevixibat
  - Alagille syndrome: E.U.
  - FOP: U.S.

**Guidance**
- **Total-sales growth**: greater than 6.0% (at constant exchange rates)

**Core operating margin**: around 30% of total sales